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Cervical cancer is the most common cancer among women in the Indonesian population, yet little is known about the prevalence of
human papillomavirus (HPV). We investigated age-specific prevalence of HPV types and possible risk factors of HPV positivity in a
population-based sample of 2686 women, aged 15–70 years, in Jakarta, Tasikmalaya, and Bali, Indonesia. The overall HPV prevalence
was 11.4%, age-standardized to the world standard population 11.6%. The most prevalent types found were HPV 52, HPV 16, HPV 18,
and HPV 39, respectively, 23.2, 18.0, 16.1, and 11.8% of the high-risk HPV types. In 20.7% of infections, multiple types were involved.
Different age-specific prevalence patterns were seen: overall high in Jakarta, and in Tasikmalaya, and declining with age in Bali. The
number of marriages was most associated with HPV positivity (OR 1.81 95% CI 1.31–2.51)). Remarkably, in Indonesia HPV 16 and
HPV 18 are equally common in the general population, as they are in cervical cancer. HPV 52 was the most prevalent type in the
general population, suggesting that this type should be included when prophylactic HPV vaccination is introduced in Indonesia.
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Cervical cancer is the most common cancer in women in
Indonesia, as in most developing countries (Tjindarbumi and
Mangunkusumo, 2002; Parkin et al, 2005). From hospital-based
data, it accounts for 28.6% of female cancers in Indonesia
(Tjindarbumi and Mangunkusumo, 2002).
Human papillomavirus (HPV) prevalence, age-specific
prevalence, and type of distribution differ substantially between
populations (Clifford et al, 2005; Franceschi et al, 2006) and HPV
18 has a greater role in cervical cancer in Indonesia than in the rest
of the world. HPV 18 was found as frequently as HPV 16 in cervical
cancer (Schellekens et al, 2004), or even more frequently than HPV
16 (Bosch et al, 1995). A small hospital-based case–control study
conducted in Jakarta also found a high prevalence of HPV 18 in
controls (de Boer et al, 2006). In view of the lack of population-based
relevant data, we report here the age-specific prevalence data for
HPV among women in Jakarta and Tasikmalaya on the island of
Java and among women on the island of Bali, and assess possible
risk factors in the aetiology of cervical cancer.
MATERIAL AND METHODS
This population-based study was conducted as part of a screening
project for cervical cancer in Jakarta and Tasikmalaya on the
island of Java and different regions on the island of Bali in
Indonesia between October 2004 and February 2006. Women were
excluded if they were virgin, pregnant, had undergone a
hysterectomy, or had previous cervical cancer. During our study
it appeared that only married, divorced or widowed women
participated in screening. Women who had never been married
would strictly still be virgins because sexual intercourse before
marriage is not allowed following Indonesia’s cultural and
religious rules.
To reach women, in each region a collaboration was set up with
the Pembinaan Kesejahteraan Keluarga (PKK), the national
Indonesian Family Welfare Organization. The smallest branches
of this governmental women’s movement organise activities at the
village level. The attempt was made to invite all women aged 20–65
years in the selected villages and to screen at least 80% of these.
Members of this local PKK invited participation by visiting women
at home and informing them about risk factors, prevention, early
detection, and treatment of premalignant cervical cancer lesions.
Participants were individually counselled by public health nurses
and their informed consent obtained; all were interviewed about
socio-demographic, reproductive and cervical cancer risk factors.
A total of 20834 women, aged 12–70, were screened: 6274 from
Jakarta, 8007 from Tasikmalaya, and 6553 from Bali. For the HPV
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ytyping, a random age-stratified sample of the participants was
taken for each region by categorising the women in 11 5-year age
groups: p19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,
55–59, 60–64, and X65 years. In each age group, 100 randomly
selected samples were used for HPV analysis. As the youngest and
oldest groups were under-represented (o100 women), the total
samples was less than 1100 per region. For Jakarta 915 were
selected, for Tasikmalaya 975, and for Bali 950 samples.
Participants underwent a visual inspection of the cervix and a
smear obtained using a wooden Ayre spatula for the ectocervix and
a cytobrush for the endocervix. Slides were immediately fixed with
ethanol and further processed for diagnosing by cytoscreeners.
The exfoliated cells remaining on the spatula and brush were
suspended in 25ml of phosphate-buffered saline in a 50ml Falcon
tube. The tubes were centrifuged at 3000g for 5min. The
supernatant was removed, and the cell pellet was re-suspended
in 1ml of phosphate-buffered saline and transferred to a 1.5ml
Eppendorf tube with a safety lock. All tubes were directly frozen
and stored in a  201C freezer and shipped on dry ice to the
Department of Pathology, Leiden University Medical Center, the
Netherlands.
Furthermore, all women underwent visual inspection with acetic
acid and those women with acetowhite lesions and/or cytological
abnormalities were treated with cryotherapy. In cases of suspected
cervical cancer the women were referred to the collaborating
university hospitals.
To test the quality of DNA obtained from exfoliated cells, a
polymerase chain reaction on the human genomic b-globin gene
was performed. HPV DNA detection and genotyping was
performed, amplified using the SPF10 primer and HPV amplimers
tested on agarose gels (Kleter et al, 1999).
The genotyping of positive products was performed using an
INNO-line probe assay prototype research genotyping assay
(Innogenetics, Ghent, Belgium which detected the following 25
types: HPV 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52,
53, 54, 56, 58, 59, 66, 68, 70, and 74. High-risk types were identified
using the HPV well known categories (Longuet et al, 1996; Munoz
et al, 2003).
Statistical analysis
Statistical analysis was performed using SPSS software (SPSS,
version 12, SPSS Inc., Chicago, IL, USA). For each region odds
ratios (ORs) and 95% confidence intervals (CIs) using uncondi-
tional multiple logistic regression adjusted for age were calculated
to estimate the association between HPV infections and risk
factors adjusted for age. To test for linear trend for odds ratios, a
w
2 linear test was calculated. Age standardization of rates for ages
15–70 was calculated using the world standard (Segi, 1960).
RESULTS
Of the 2840 patients, 114 cellular samples were missing (26 Jakarta,
48 Tasikmalaya, 40 Bali). Of the remaining 2726, 40 samples were
excluded because of a negative b-globin test (9 from Jakarta, 8
from Tasikmalaya, and 23 from Bali), of the final study group
(2686 samples: 880 Jakarta, 919 Tasikmalaya, 887 from Bali). 91.2%
had never been screened before, 80.7% from Jakarta, 97.4%
Tasikmalaya and 95.6% Bali. Based on cytology, five of 880 women
in Jakarta were diagnosed with cervical cancer, four of the 919 in
Tasikmalaya and three of the 887 in Bali. Based on visual
inspection with acetic acid, there were also two suspected cases
in Tasikmalaya. In 13 of the 14 cases, the diagnoses were
histologically confirmed and in the other the woman repeatedly
refused follow up.
Overall, 305 samples (11.4%) were HPV positive (11.6% when
world age-standardized), in Jakarta 122 samples (13.9% standardized
13.2%) were HPV positive, in Tasikmalaya 81 (8.8% standardized
9.0%), and in Bali 102 samples (11.5% standardized 12.1%). In
total, in 211 samples (7.9%) high-risk HPV type was detected: 77
(8.9%) in Jakarta; 62 (6.7%) in Tasikmalaya and 72 (8.1%) in Bali.
Forty-six samples (22 from Jakarta, 8 from Tasikmalaya, and 16
from Bali) were positive by the SPF10 primer set but not for HPV
types represented in the line probe assay; these indicated as HPV X
could not be categorised as cancer-associated or non-cancer-
associated types.
Twenty-four different HPV types were detected, the commonest
in descending order of prevalence being HPV 52, 16, and 18. This
most differed by region, as shown in Table 1. Multiple HPV types
were detected in 63 samples (2.3% overall, or 20.7% of all positive
samples): in Jakarta in 22 (2.5 or 18.0%), in Tasikmalaya in 15
(1.6 or 18.5%), and in Bali in 26 (2.9 or 25.5%).
In the 14 cervical cancer cases, single HPV 52 infection was
detected in three and HPV 18 was also detected in three cases
including one multiple infection with HPV 6. HPV 16 was detected
two times, HPV 31, HPV 33 and HPV 39, HPV42 and HPV 45 were
detected once. In one cancer case, HPV could not be detected.
The age-specific prevalence overall, and by region is shown in
Figure 1. The overall age-specific prevalence in Indonesia was high
in all ages (X9.8%), and ranged from 9.8 to 13.3%. In Jakarta, the
overall prevalence was high (X9.3%), with two peaks: one of 18.4%
in the 35–44 year age group and a second, of 15.4%, in women
older than 54 years. The age-specific prevalence in Tasikmalaya
peaked at 8.8% in the youngest age group of o25 years, declined
to 4.7% in the 25–34 year group, and formed a second peak at
11.5% in the 45–54 year group. In Bali, HPV prevalence declined
with age, from 14.7% in the o25 year group to 7.4% in the 454
year group, the trend in this decline was significant (Po0.01).
Risk factors for HPV infection
The association between HPV infection and characteristics of the
studied women overall and by region after adjustment for age are
shown in Table 2. Overall, being screened before was associated
with a higher HPV positivity than never being screened before
(OR 1.67, 95% CI 1.13–2.44) as was having had more than one
partner than women having had one partner (OR 1.81, 95% CI
1.31–2.51). In Jakarta, HPV positivity was inversely associated
with daily income when women having XUS $3 per day were
compared with those with pUS $1 per day (OR 0.51, 95% CI 0.28–
0.92, with a significant trend of P¼0.02), while having had more
than one partner was associated with a higher HPV positivity than
one partner (OR 2.66, 95% CI 1.64–4.33). In Tasikmalaya, the few
divorced women had an OR of 6.0 (95% CI 1.39–25.91) with HPV
positivity compared with married women. Although not
significant, it seemed that nulliparous women were more often
HPV positive (OR 5.35, 95% CI 0.92–31.08) than women with 1–2
children. In Bali, being 55 years or older was inversely associated
with positivity (OR 0.46, 95% CI 0.23–0.96). In contrast with
Jakarta, in Bali higher daily income was associated with higher
positivity (OR 1.91, 95% CI 1.08–3.38, with a trend of P¼0.03). In
all three regions, HPV positivity was unrelated to having had a
previous Pap smear, education level, smoking, the number of
miscarriages, age at menarche, age at marriage, or first pregnancy.
DISCUSSION
Among a mainly unscreened population of women in Indonesia,
we found an intermediate overall prevalence of HPV, highest types
52, 16, and 18, with a different age specific pattern in the three
regions.
Clifford et al defined age-standardized HPV prevalence rates as
‘low’, ‘intermediate’, and ‘high’. Using a previous classification, the
overall prevalence found (11.3%) was intermediate (Clifford et al,
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y2005), comparable to other Asian countries like Thailand
(Lampang, 9.1%), Vietnam (Ho Chi Minh City, 10.6%), India
(17.7%), and with South American countries such as Chile (14.0%)
and Mexico (14.5%) (Lazcano-Ponce et al, 2001; Pham et al, 2003;
Sukvirach et al, 2003; Ferreccio et al, 2004; Franceschi et al, 2005).
Cervical cancer incidence is related to HPV prevalence in the
region and the presence of organised screening, among other
factors (Bosch and de Sanjose, 2003) and that estimated for
Indonesia, a country without organised screening (at least 30 per
100000 women per year) is consistent with recorded HPV
(Schellekens et al, 2004; Parkin et al, 2005) prevalence.
Areas of high HPV prevalence and with no decline in older age
groups all have high incidence and mortality and very low income
levels (Franceschi et al, 2006), as is true for Jakarta and
Tasikmalaya.
In contrast, in Bali a significant decline in HPV prevalence with
increasing age was seen, as in some western countries, in Korea
(Franceschi et al, 2006) and among Hindu women in India
(Duttagupta et al, 2004). In the latter, the reproductive period (and
thus active sexual life) of Hindu women mostly ends by the age of
30–35 years, which could explain the decreasing prevalence
observed. Genetic factors in the susceptibility to HPV infection
in older age could not be excluded. Unfortunately, we lack such
information for Hindu women in our study.
Two potential selection biases could have occurred: we
attempted to screen at least 80% of all women aged 20–65 in the
villages who were visited by the screening programme. All women
were informed at their homes but only the women who actually
answered the call to participate were included. The percentage of
targeted women included was only available for Bali, (83.7%).
Because the method of selection was similar in all regions, and
because all households in an area were visited, we assume that
participation is similar to that in Bali. The major reasons for
















Figure 1 Age-specific prevalence of cervical human papillomavirus
(HPV) DNA in percentages with 95% CI (Overall, Jakarta, Tasikmalaya and
Bali, Indonesia).
Table 1 Prevalence of type-specific cervical human papilloma infection types among 2686 women in Indonesia
Jakarta (880) Tasikmalaya (919) Bali (887)
HPV type
a Single Multiple Total
b (%) HPV+
c (%) Single Multiple Total
b (%) HPV+
c (%) Single Multiple Total
b (%) HPV+
c (%)
Negative 758 (86.1) 838 (91.2) 785 (88.5)
Positive 100 22 122 (13.9) 66 15 81 (8.8) 76 26 102 (11.5)
High risk 56 22 78 (8.9) 63.9 47 15 62 (6.7) 76.5 52 25 77 (8.9) 75.4
Low risk 22 — 22 (2.5) 18.0 11 — 11 (1.2) 13.6 8 1 9 (1.0) 8.8
X 22 — 22 (2.5) 18.0 8 — 8 (0.9) 9.9 16 — 16 (1.8) 15.7
High risk
16 10 3 13 (1.5) 10.7 5 5 10 (1.1) 12.3 8 7 15 (1.7) 15.0
18 5 3 8 (0.9) 6.6 10 4 14 (1.5) 17.3 7 5 12 (1.4) 12.0
31 — 1 1 (0.1) 0.8 1 — 1 (0.1) 1.2 2 1 3 (0.3) 3.0
33 1 1 2 (0.2) 1.6 — 1 1 (0.1) 1.2 3 3 6 (0.7) 5.9
35 3 — 3 (0.3) 2.5 2 1 3 (0.3) 3.7 2 — 2 (0.2) 2.0
39 7 4 11 (1.3) 9.0 7 1 8 (0.9) 9.9 3 3 6 (0.7) 6.0
45 — 4 4 (0.5) 3.3 — 1 1 (0.1) 1.2 2 4 6 (0.7) 6.0
51 6 4 10 (1.1) 8.2 2 2 4 (0.4) 4.9 7 1 8 (0.9) 8.0
52 13 5 18 (2.0) 14.8 8 5 13 (1.4) 16 10 8 18 (2.0) 18.0
53 3 2 5 (0.6) 4.1 3 3 6 (0.7) 7.4 1 — 7 (0.8) 7.0
56 6 1 7 (0.8) 5.7 4 2 6 (0.7) 7.4 1 5 6 (0.7) 6.0
58 1 — 1 (0.1) 0.8 2 — 2 (0.2) 2.5 — 2 2 (0.2) 2.0
59 1 1 2 (0.2) 1.6 — — — — — —
66 — 1 1 (0.1) 0.8 1 — 1 (0.1) 1.2 2 2 4 (0.5) 4.0
68 — 3 3 (0.3) 2.5 2 — 2 (0.2) 2.5 4 1 5 (0.6) 5.0
Low risk
6 5 3 8 (0.9) 6.6 — 2 2 (0.2) 2.5 4 2 6 (0.7) 6.0
11 — — — — — — — 1 1 (0.1) 1.0
40 — — — — 1 1 (0.1) 1.2 1 1 2 (0.2) 2.0
42 — — — 1 — 1 (0.1) 1.2 — — —
43 2 — 2 (0.2) 1.6 1 2 3 (0.3) 3.7 — 2 2 (0.2) 2.0
44 1 2 3 (0.3) 2.5 1 1 2 (0.2) 2.5 1 2 3 (0.3) 3.0
54 4 2 6 (0.7) 4.9 2 1 3 (0.3) 3.7 — 2 2 (0.2) 2.0
70 4 4 8 (0.9) 6.6 5 2 7 (0.8) 8.6 2 4 6 (0.7) 6.0
74 6 1 7 (0.8) 5.7 1 — 1 (0.1) 1.2 — 2 2 (0.2) 2.0
aThe same woman can be counted more than once because of multiple infections.
bPercentage over all women.
cPercentage over HPV-positive cases.
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ysecond bias concerns the fact that culturally and religiously, sexual
intercourse is not allowed before marriage in Indonesia. For this
reason a few questions were believed to be inappropriate and
thought not to be answered honestly. Instead we asked acceptable
questions: ‘age of first marriage’ and ‘number of marriages’. We
did not perform gynaecological examination on unmarried women
who would strictly still be virgin; all our screened women were
married, divorced or widowed.
HPV 52 was the most prevalent type in Jakarta and Bali, and the
second most prevalent type (after 18) in Tasikmalaya accounting,
respectively, for 23.1, 20.1, and 23.4% of the high-risk positive
samples. Worldwide, high prevalence of HPV 52 is also reported
from China, Taiwan, and Costa Rica (Herrero et al, 2005; Jeng et al,
2005; Dai et al, 2006). It was also detected, in 21.4% (three of 14) of
the cervical cancers as it was in 14% of cases in another study
(Schellekens et al, 2004). Clifford et al (2003) also identified HPV
52 more frequently in cervical cancer in Asia than in other parts of
the world. Adding HPV 52, to types 16 and 18, in a prophylactic
HPV vaccine when introduced in Indonesia would therefore seem
appropriate.
HPV 16 prevalence in this population was comparable to that in
most parts of the world (Clifford et al, 2005), though that of HPV
18 was higher than regions with comparable overall HPV
prevalence (Lazcano-Ponce et al, 2001; Pham et al, 2003; Sukvirach
et al, 2003; Ferreccio et al, 2004; Franceschi et al, 2005). HPV 18
accounted for a significant population of high-risk HPV-positive
samples: 10.3, 22.6, and 15.6%, respectively, for Jakarta, Tasikmalaya,
and Bali. In most countries, HPV 16 is by far the most prevalent
type in cervical carcinoma and in the general population, followed
by HPV 18 (Clifford et al, 2003, 2005). Although we found small
inter-regional differences (see Table 1), HPV 18 was as common as
16, reflecting their predominant roles in cervical cancer in
Indonesia (Bosch et al, 1995; Schellekens et al, 2004). HPV 39
was prevalent in the general population in this study, but it is rare
in cervical carcinomas in Indonesia and other parts of Asia
(Clifford et al, 2003; Schellekens et al, 2004).
As expected, a history of more than one sexual partner was
associated with HPV positivity (Vaccarella et al, 2006a,b). A small
group of divorced women in Tasikmalaya and women with high
daily income in Bali were associated with HPV positivity, probably
Table 2 ORs for HPV detection and corresponding 95% CI
Overall Jakarta Tasikmalaya Bali
HPV HPV HPV HPV HPV HPV HPV HPV
neg pos OR
a (95% CI) neg pos OR
a (95% CI) neg pos OR
a (95% CI) neg pos OR
a (95% CI)
Age
o25 365 47 1 112 13 1 125 12 1 128 22 1
25–34 509 63 0.96 (0.64–1.44) 165 27 1.41 (0.70–2.85) 183 9 0.51 (0.21–1.25) 161 27 0.98 (0.53–1.79)
35–44 494 76 1.20 (0.81–1.76) 155 35 1.95 (0.98–3.85) 175 17 1.01 (0.47–2.19) 164 24 0.85 (0.46–1.59)
45–54 495 54 0.85 (0.56–1.28) 156 16 0.88 (0.41–1.91) 170 22 1.35 (0.64–2.83) 169 16 0.55 (0.28–1.09)
X55 518 65 0.97 (0.65–1.45) 170 31 1.57 (0.79–3.13) 185 21 1.18 (0.56–2.49) 163 13 0.46 (0.23–0.96)
Trend 0.48 0.63 0.11 0.01
Screened before
No 2186 267 1 615 95 1 817 78 1 754 94 1
Yes 187 37 1.67 (1.13–2.44) 141 27 1.25 (0.76–2.05) 19 3 1.43 (0.41–5.00) 27 7 1.98 (0.83–4.75)
Salary
o1$ per day 840 104 1 99 23 1 371 42 1 370 39 1
1–3$ per day 861 109 1.01 (0.76–1.35) 353 61 0.77 (0.45–1.30) 224 13 0.53 (0.27–1.01) 284 35 1.11 (0.68–1.81)
43$ per day 583 75 1.03 (0.75–1.42) 257 31 0.51 (0.28–0.92) 214 21 0.82 (0.47–1.45) 112 23 1.91 (1.08–3.38)
Trend 0.80 0.02 0.41 0.03
Marital status
Married 2260 287 1 683 111 1 795 74 1 783 102 1
Divorced 10 4 2.96 (0.92–9.55) 5 1 1.12 (0.13–9.85) 5 3 6.0 (1.38–25.91) 0 0 0
Widowed 109 14 1.07 (0.59–1.93) 70 10 0.85 (0.40–1.80) 39 4 0.9 (0.31–2.64) 0 0 0
Age at marriage
o16 287 42 1 96 21 1 144 16 1 47 5 1
16–18 449 56 0.85 (0.55–1.30) 218 33 0.70 (0.38–1.28) 325 31 0.92 (0.48–1.74) 217 34 1.49 (0.55–4.03)
19–21 535 62 0.79 (0.52–1.20) 242 32 0.60 (0.33–1.10) 224 21 0.96 (0.48–1.92) 328 37 1.21 (0.44–3.28)
421 1104 145 0.89 (0.62–1.29) 202 36 0.79 (0.43–1.45) 144 13 0.92 (0.42–2.02) 188 26 1.37 (0.49–3.87)
Trend 0.67 0.64 0.61 0.84
Number of marriages
1 2112 250 1 675 92 1 687 61 1 750 97 1
41 261 55 1.81 (1.31–2.51) 82 30 2.66 (1.64–4.33) 149 20 1.40 (0.81–2.43) 30 5 1.51 (0.56–4.06)
Parity
0 22 3 1.03 (0.30–3.50) 9 1 0.76 (0.09–6.23) 4 2 5.34 (0.92–31.06) 9 0 0
1/2 1063 138 1 302 41 1 333 33 1 428 64 1
3/4 719 87 0.91 (0.67–1.25) 233 47 1.43 (0.84–2.41) 272 20 0.60 (0.31–1.15) 214 20 0.71 (0.40–1.28)
X5 455 58 0.99 (0.66–1.47) 172 23 0.96 (0.50–1.85) 175 25 1.09 (0.54–2.20) 108 10 0.82 (0.35–1.90)
Trend 0.83 0.73 0.51 0.11
OR¼odds ratio, CI¼confidence interval. Figures do not add up to the total because of missing values.
aAdjusted for age.
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yreflecting their sexual behaviour and that of their partners
(Vaccarella et al, 2006a). Unfortunately, little relevant information
is available because sexuality is still a taboo subject in Indonesia;
more research could be revealing. Overall, previous screening was
associated with higher HPV positivity. Possibly, reflecting earlier
symptoms.
In conclusion, in Indonesia HPV 16 and 18 are equally common
in the general population, as they are in cervical cancer. HPV 52
was the most prevalent type, suggesting that it should also be
included in the prophylactic HPV vaccine when introduced in
Indonesia.
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